Eptifibatide 1mg
Product Details:
Product Name :Eptifibatide
Certification:SGS/ISO9001/Kosher
Place of Origin:China
Minimum Order Quantity:10 vials
Price:Negotiation
Payment Terms:Western Union,Money Gram ,Bitcoin or T/T
Supply Ability:5000 Vial per month
Delivery Time:After receipt of your payment
Packaging Details:Original Kits or as requirements
Product Name:Eptifibatide,Peptide Hormones,Bodybuilding Supplements
Manufacturer:HKYCGC
Contact Person:Lynn
Email:beststeroids@chembj.com
Skype:best.steroids
Eptifibatide 1mg
Product Name:Eptifibatide
Unit Size :1 mg/vial
Unit Quantity :1 Vial
Synonyms :GDF-8
Appearance :White Powder
Purity :99%
Source :Chemical Synthesis
Storage :Lyophilized Eptifibatide is stable at room temperature for 90 days,however it should be stored in a freezer below -8C for any extended period of time. After reconstituting MGF should be refrigerated at temperatures not to exceed 36 F.
Description:
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Integrilin is sold in two strengths, globally: vials containing 2 mg/ml (20 mg totally) and 0.75 mg/ml (75 mg totally). A third size is sold in the US: 100 ml vials containing 2 mg/ml (200 mg totally).
Indications:
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.